Guillain–Barré syndrome (GBS) is a rare immune-mediated acute polyradiculo-neuropathy
that typically develops after a previous gastrointestinal or respiratory infection. This narrative …

Introduction On March 11, 2020, the World Health Organization sounded the COVID-19
pandemic alarm. While efforts in the first few months focused on reducing the mortality of …

SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate
but occasionally severe. One of these severe side effects is Guillain-Barré syndrome (GBS) …

Abstract Coronavirus disease 2019 (COVID‐19) has been shown to be associated with a lot
of neurological complications, of whom Guillain‐Barre syndrome (GBS) is an important post …

Since the introduction of mRNA technology‐based and vector‐based COVID‐19 vaccines,
adverse reactions to these agents have been occasionally reported. Exacerbation of Guillain …

Background: This mini-review aims to summarize and discuss previous and recent
advances in the clinical presentation, pathophysiology, diagnosis, treatment, and outcome of …

Abstract Coronavirus disease 2019 (COVID-19) is a real challenge for humanity with high
morbidity and mortality. Despite being primarily a respiratory illness, COVID-19 can affect …

Guillain-Barré syndrome (GBS) is an immune-mediated inflammatory
polyradiculoneuropathy, which commonly leads to a very high level of neurological …

Background The characteristic symptom of coronavirus disease 2019 (COVID-19) is
respiratory distress, but neurological symptoms are the most frequent extra-pulmonary …

Background To assess whether SARS-CoV-2 infection may affect the central nervous
system, specifically neurons and glia cells, even without clinical neurological involvement …